3 unknown, 1 recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow HRD: new trials by email Literature Review of HRD trials Research Report on HRD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma Niraparib, Dostarlimab - HRD, Cholangiocarcinoma | Phase 2 | Withdrawn | Walid Shaib, MD | 2021-10-11 | 2022-06-29 | |
| Variance of HRD From Paired Ovarian Cancer Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 50 | 2021-10-01 | 2021-10-06 | |
| Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients PARP inhibitor - Ovarian Cancer, HRD | Unknown | Xiaoxiang Chen | 100 | 2021-09-15 | 2021-09-14 | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer AZD6738, Olaparib, Durvalumab - Breast Neoplasm, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 119 | 2019-10-15 | 2025-08-11 |
| Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors HWH340 tablet - Advanced Solid Tumors, HRD | Phase 1 | Unknown | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | 85 | 2018-03-05 | 2020-02-17 |
Ovarian Neoplasms (2) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Kenny-Caffey syndrome, Type 1 (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (3) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1)
niraparib (2) · olaparib (2) · Poly(ADP-ribose) Polymerase Inhibitors (1) · ceralasertib (1) · dostarlimab (1) · durvalumab (1)
Xiaoxiang Chen (2) · Hubei Biological Medicine Industrial Technology Institute Co., Ltd. (1) · Institute of Cancer Research, United Kingdom (1) · Walid Shaib, MD (1)
China (3) · United Kingdom (1)
Andrew Tutt (1) · Walid Shaib, MD (1) · Xiaoxiang Chen Chen, MD,PhD (1) · Xiaoxiang Chen, MD,PhD (1)
2018 (1)